Vir Biotechnology
The role supports partnered and internal research programs from discovery through early clinical development, driving integrated planning, cross‑functional collaboration, and risk management. It also contributes to broader research operations and strategic initiatives, acting as a strategic partner to research leadership.
Headquarters
San Francisco, California, United States
Company Size
501-1000 employees
Founded
2016
Vir Biotechnology is a clinical-stage immunology company that leverages the immune system to address critical unmet medical needs in infectious diseases and oncology. Its pipeline is built on two core technology platforms: a next-generation antibody and T-cell engager platform focused on infectious diseases, and the PRO-XTEN® protease-releasable masking technology applied to oncology and infectious disease. With foundational programs including chronic hepatitis delta, COVID-19, and Ebola, Vir works to engineer antibody-based medicines and deliver potentially transformative treatments to patients worldwide.
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
3 weeks ago
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from Analysts
4 days ago
Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Vir Biotechnology.
41% above the average for this role
Astellas, Vir Biotechnology Launch Up-to-$1.7B Prostate Cancer Collaboration
3 weeks ago
Director, Discovery Research Program Management
AbbVie
Senior Director, CMC Project Management, Bioconjugate Modalities
Eli Lilly and Company
VP, Head of Research US Oncology
Servier
Principal Research Scientist I - Functional Reprograming Team Lead
AbbVie
Research Product Lead, Immunology
CSL Behring Australia
Global Therapeutic Research Lead - Immunology
Takeda Pharmaceutical Company Limited